Investigating the safety and efficacy of mesenchymal stem cells secretome injection in female androgenetic alopecia

Phase 1

Recruiting

• Conditions: Hair Loss.; Nonscarring hair loss, unspecified; L65.9

• Registration Number: IRCT20200127046282N41
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

patients with female androgenetic alopecia grade 5
Patients aged 30 to 45 years
Hormonally healthy patients

Exclusion Criteria

Presence of evidence of sepsis, immunosuppression and cancer
Use of oral drug treatment for androgenic hair loss (such as finasteride, dutasteride or any other anti-androgen drug) in 12 months the past
Use of local drug treatment of androgenic hair loss (such as minoxidil, prostaglandin analogues, retinoids orCorticosteroids) in the last 12 months
Discovering another cause for the patient's hair loss
Non-cooperation of the patient until the end of the study

Study & Design

• Study Type: interventional
• Study Design: Not specified